Magnitude of Lamotrigine Exposure Through Breastfeeding
Importance: Lamotrigine use during breastfeeding has significantly increased in the recent years, whereas breast milk lamotrigine pharmacokinetics data are still sparse. Objectives: To assess lamotrigine exposure in breastfed infants by monitoring maternal serum and breast milk concentrations. Methods: Breastfeeding women treated with lamotrigine were recruited to this study. Maternal trough breast milk and serum samples were collected, and additional breast milk samples were collected 1, 3, 6, 9, 12 hours after lamotrigine consumption. Trough breast milk/serum ratios (M/S ratio) and breast milk area under the curve (AUC) values were calculated. Results: Twenty-one breastfeeding women were recruited to this study, and the final dataset was based on the samples collected from 17 women. Lamotrigine trough serum and mother's milk concentrations were 5.1 ± 3.3 mg/L and 3.1 ± 1.9 mg/L, respectively (mean ± standard deviation). The trough M/S ratio of lamotrigine was 0.66 ± 0.22. The lamotrigine breast milk average AUC was 41.7 ± 24.6 mg·h/L. The estimated infant dose of lamotrigine was 0.52 ± 0.31 mg/kg/day and 0.26 ± 0.15 mg/kg/day for fully and partially breastfed infants, respectively. Significant correlation was found between the maternal lamotrigine serum trough concentrations and the breast milk parameters: trough breast milk concentrations (Spearman's rho = 0.986, p < 0.0001) and breast milk AUC values (Spearman's rho = 0.941, p < 0.0001). No significant correlation was found between the maternal lamotrigine daily dose and serum trough concentrations, breast milk trough concentrations, and breast milk AUC values (Spearman's rho = 0.294, 0.285, and 0.438, p = 0.252, 0.396, and 0.078, respectively). Conclusion and Relevance: High correlation between the maternal lamotrigine trough serum concentrations and the breast milk AUC values was found, implying that monitoring the maternal lamotrigine serum concentrations can be useful for prediction of exposure of infants to lamotrigine through the breast milk. The trial was registered in the Israeli trials registry MOH_2021-09-05_010243 at September 5, 2021 Retrospectively registered https://my.health.gov.il/CliniTrials.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
|---|---|
| Enthalten in: |
Breastfeeding medicine : the official journal of the Academy of Breastfeeding Medicine - 17(2022), 4 vom: 20. Apr., Seite 341-348 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kohn, Elkana [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
AUC |
|---|
| Anmerkungen: |
Date Completed 12.04.2022 Date Revised 29.06.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1089/bfm.2021.0304 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM335839916 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM335839916 | ||
| 003 | DE-627 | ||
| 005 | 20231225230755.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1089/bfm.2021.0304 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1119.xml |
| 035 | |a (DE-627)NLM335839916 | ||
| 035 | |a (NLM)35049332 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kohn, Elkana |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Magnitude of Lamotrigine Exposure Through Breastfeeding |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.04.2022 | ||
| 500 | |a Date Revised 29.06.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Importance: Lamotrigine use during breastfeeding has significantly increased in the recent years, whereas breast milk lamotrigine pharmacokinetics data are still sparse. Objectives: To assess lamotrigine exposure in breastfed infants by monitoring maternal serum and breast milk concentrations. Methods: Breastfeeding women treated with lamotrigine were recruited to this study. Maternal trough breast milk and serum samples were collected, and additional breast milk samples were collected 1, 3, 6, 9, 12 hours after lamotrigine consumption. Trough breast milk/serum ratios (M/S ratio) and breast milk area under the curve (AUC) values were calculated. Results: Twenty-one breastfeeding women were recruited to this study, and the final dataset was based on the samples collected from 17 women. Lamotrigine trough serum and mother's milk concentrations were 5.1 ± 3.3 mg/L and 3.1 ± 1.9 mg/L, respectively (mean ± standard deviation). The trough M/S ratio of lamotrigine was 0.66 ± 0.22. The lamotrigine breast milk average AUC was 41.7 ± 24.6 mg·h/L. The estimated infant dose of lamotrigine was 0.52 ± 0.31 mg/kg/day and 0.26 ± 0.15 mg/kg/day for fully and partially breastfed infants, respectively. Significant correlation was found between the maternal lamotrigine serum trough concentrations and the breast milk parameters: trough breast milk concentrations (Spearman's rho = 0.986, p < 0.0001) and breast milk AUC values (Spearman's rho = 0.941, p < 0.0001). No significant correlation was found between the maternal lamotrigine daily dose and serum trough concentrations, breast milk trough concentrations, and breast milk AUC values (Spearman's rho = 0.294, 0.285, and 0.438, p = 0.252, 0.396, and 0.078, respectively). Conclusion and Relevance: High correlation between the maternal lamotrigine trough serum concentrations and the breast milk AUC values was found, implying that monitoring the maternal lamotrigine serum concentrations can be useful for prediction of exposure of infants to lamotrigine through the breast milk. The trial was registered in the Israeli trials registry MOH_2021-09-05_010243 at September 5, 2021 Retrospectively registered https://my.health.gov.il/CliniTrials | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a AUC | |
| 650 | 4 | |a breastfeeding | |
| 650 | 4 | |a drug levels | |
| 650 | 4 | |a infant's exposure | |
| 650 | 4 | |a lamotrigine | |
| 650 | 7 | |a Anticonvulsants |2 NLM | |
| 650 | 7 | |a Lamotrigine |2 NLM | |
| 650 | 7 | |a U3H27498KS |2 NLM | |
| 700 | 1 | |a Dinavitser, Natalie |e verfasserin |4 aut | |
| 700 | 1 | |a Berlin, Maya |e verfasserin |4 aut | |
| 700 | 1 | |a Brandriss, Nurit |e verfasserin |4 aut | |
| 700 | 1 | |a Bar-Chaim, Adina |e verfasserin |4 aut | |
| 700 | 1 | |a Gueta, Itai |e verfasserin |4 aut | |
| 700 | 1 | |a Keidar, Rimona |e verfasserin |4 aut | |
| 700 | 1 | |a Livne, Ayelet |e verfasserin |4 aut | |
| 700 | 1 | |a Stepensky, David |e verfasserin |4 aut | |
| 700 | 1 | |a Berkovitch, Matitiahu |e verfasserin |4 aut | |
| 700 | 1 | |a Masarwi, Majdi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Breastfeeding medicine : the official journal of the Academy of Breastfeeding Medicine |d 2006 |g 17(2022), 4 vom: 20. Apr., Seite 341-348 |w (DE-627)NLM171765958 |x 1556-8342 |7 nnns |
| 773 | 1 | 8 | |g volume:17 |g year:2022 |g number:4 |g day:20 |g month:04 |g pages:341-348 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1089/bfm.2021.0304 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 17 |j 2022 |e 4 |b 20 |c 04 |h 341-348 | ||